Fraxamoside is a xanthineoxidase inhibitor (XOI) comparable in potency in vitro to the standard antigout drug allopurinol. It shows significant free radical scavenging effect against DPPH(EC50=62.6 uM).
Xanthineoxidase-IN-5, a powerful and orally active inhibitor of xanthineoxidase (XO), exhibits an IC50 value of 0.70 μM. It possesses favorable drug-like characteristics, with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Moreover, Xanthineoxidase-IN-5 showcases significant hypouricemic effects in a hyperuricemic rat model [1].